A number of firms have modified their ratings and price targets on shares of Humana (NYSE: HUM) recently:

  • 5/2/2019 – Humana had its price target lowered by analysts at Oppenheimer Holdings Inc. from $373.00 to $350.00. They now have an “outperform” rating on the stock.
  • 5/2/2019 – Humana had its price target lowered by analysts at Credit Suisse Group AG from $352.00 to $315.00. They now have an “outperform” rating on the stock.
  • 5/2/2019 – Humana was given a new $331.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 5/2/2019 – Humana had its price target lowered by analysts at Citigroup Inc from $362.00 to $302.00. They now have a “buy” rating on the stock.
  • 5/2/2019 – Humana had its price target lowered by analysts at SunTrust Banks, Inc. to $300.00.
  • 4/23/2019 – Humana is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $266.00 price target on the stock.
  • 4/17/2019 – Humana had its price target lowered by analysts at Barclays PLC from $351.00 to $327.00. They now have an “overweight” rating on the stock.
  • 4/11/2019 – Humana was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 4/11/2019 – Humana was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Humana’s shares have lost year-to-date against its industry’s gain. Moreover, the company has witnessed its 2020 earnings estimates move south over the last 30 days. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. Also, increase in leverage might lead to heightened financial risk for the company and burden on margins. Nevertheless, it is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters.”

Shares of NYSE:HUM opened at $247.82 on Monday. The company has a market cap of $33.46 billion, a P/E ratio of 17.03, a P/E/G ratio of 1.02 and a beta of 0.88. Humana Inc has a 1 year low of $225.65 and a 1 year high of $355.88. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.65 and a current ratio of 1.65.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.30 by $0.18. The business had revenue of $16.11 billion for the quarter, compared to the consensus estimate of $15.67 billion. Humana had a return on equity of 20.77% and a net margin of 2.99%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.36 earnings per share. On average, analysts anticipate that Humana Inc will post 17.57 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Thursday, June 27th. Humana’s dividend payout ratio is currently 15.12%.

In other Humana news, insider Christopher H. Hunter sold 15,586 shares of the company’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the completion of the sale, the insider now directly owns 28,100 shares in the company, valued at $8,577,244. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Roy A. Beveridge sold 8,278 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $307.16, for a total value of $2,542,670.48. Following the sale, the insider now owns 12,409 shares of the company’s stock, valued at $3,811,548.44. The disclosure for this sale can be found here. Corporate insiders own 0.54% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in HUM. Premia Global Advisors LLC bought a new position in shares of Humana in the 1st quarter valued at $25,000. We Are One Seven LLC bought a new position in shares of Humana in the 4th quarter valued at $31,000. Proficio Capital Partners LLC raised its position in Humana by 81.4% during the 4th quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 48 shares during the last quarter. Destination Wealth Management raised its position in Humana by 130.0% during the 1st quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 65 shares during the last quarter. Finally, Exane Asset Management bought a new position in Humana during the 4th quarter worth $43,000. Institutional investors own 94.72% of the company’s stock.

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: Reverse Stock Split

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.